Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

Not Recruiting

Trial ID: NCT01254045

Age - 13 Years-29 Years Condition - Child Psychiatry Gender - MALE Accepting Healthy Volunteers - yes

Purpose

The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.

Official Title

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

Stanford Investigator(s)

Allan L. Reiss

Howard C. Robbins Professor of Psychiatry and Behavioral Sciences and Professor of Radiology

Eligibility

Inclusion Criteria:

1. Confirmed genetic diagnosis of Fragile X (FraX) (full mutation).
2. Male (who have more serious effects due to the X chromosome nature of the disorder)
3. Age 13-29 years.
4. Parent of adolescent must be willing to sign informed consent.
5. Intelligence Quotient (IQ) \> 42.

Exclusion Criteria:

1. Cardiac risk factors.
2. Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or atypical antipsychotics.

View More
View Less

Intervention(s):

drug: placebo

drug: oxytocin 24IU

drug: oxytocin 48IU

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Scott Hall
6504984799

©2025 Stanford Medicine